Biochemical markers of bone turnover in angiographically-demonstrated coronary artery disease patients and healthy Thais.

The patients with coronary artery disease (CAD) were suffering from dyspnea. Physical activity of these patients was limited. Their lifestyle may be contributory factors for osteoporosis. Recent research has shown that biochemical markers may be used to predict future bone loss and identify individuals at risk for osteoporosis. Our objectives were to estimate reference ranges of bone markers in healthy Thais and to compare bone turnover between 105 healthy people and 118 CAD patients by using biochemical markers of bone formation and resorption. Mean values of bone markers in controls and patients were 22.9 +/- 12.9, 21.6 +/- 16.2 respectively for N-Mid osteocalcin and 0.45 +/- 0.30, 0.47 +/- 0.37 respectively for beta-Crosslaps. There was no statistical difference of N-Mid osteocalcin (p=0.50) and beta-Crosslaps (p=0.64) values between groups. Our data from this study suggested that that CAD patients have no higher risk for osteoporosis than healthy people.

Correlation of serum lipoprotein(a) with the clinical presentation of Thai coronary artery disease patients.

Elevated serum levels of lipoprotein(a) [Lp(a)] confer an increased risk of coronary artery disease (CAD) and have been confirmed as a strong and independent risk factor for this disease. This case-control study was to determine the significance of elevated Lp(a) levels for the existence of CAD by systematically recording cardiovascular risk factors in diagnostic coronary angiography in a group of patients. Two hundred thirty seven consecutive patients (175 men, 62 women, aged 61+/-10 years) which comprised 24 acute myocardial infarction (AMI), 76 unstable angina (UA) and 137 stable angina (SA) who underwent coronary angiography, were used as cases. One hundred seventy normal healthy volunteers (95 men, 75 women, and aged 58+/-15 years) were used as controls. Lp(a) concentration were measured by an immunoturbidimetric method (Roche Diagnostics, Switzerland). There was a significant difference between Lp(a) levels in UA compared with the control subjects (44.2+/-49.0 vs. 27.6+/-25.3 mg/dL, p = 0.0006). When we compared SA and the control group (35.6+/-31.3 vs. 27.6+/-25.3 mg/dL, p = 0.0139) there was a significant difference between these two groups. UA patients also had a significantly higher prevalence of abnormal Lp(a) (>30 mg/dL) compared with the normal healthy control group (43.2% UA vs. 28.8% control, OR = 1.90, 95%CI = 1.08-3.32, p = 0.0248). SA patients also had the same finding as UA patients in a higher prevalence of abnormal Lp(a) when compared with the control group (45.2% SA vs. 28.8% control, OR = 2.04, 95%CI = 1.27-3.27, p = 0.0028). These data further support the role of Lp(a) in atherosclerotic coronary disease and the pathogenesis of acute coronary syndromes.

Comparison of parathyroid hormone in angiographically-demonstrated coronary artery disease patients and healthy Thais.

Parathyroid hormone (PTH) influences the calcium metabolism. The idea of cardiovascular effects of PTH is not new. Target cells for PTH are cardiomyocytes and smooth muscle cells. Evidence from previous studies suggest that many patients with heart disease have elevated PTH concentrations. Our objective was to determine PTH status in patients with coronary artery disease (CAD). We compared intact PTH levels in 109 CAD patients with 103 healthy people by electrochemiluminescence immunoassay. Mean values of PTH in healthy Thais and CAD patients were 37.4 +/- 17.9 and 40.2 +/- 21.8 respectively. No statistical difference was shown. In addition, we compared PTH levels among various numbers of coronary occlusion and also found no differences. We propose that intact PTH concentrations in CAD patients are not higher than in the healthy population.